Oleg E. Knysh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oleg E. Knysh has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- M. I. Magdalyanova
Sverdlovsk Regional Oncological Dispensary
3 shared publications - A. Yu. Popova
Sverdlovsk Regional Oncological Dispensary
2 shared publications - D.S. Erlish
Ural State Medical University
2 shared publications - Elena Vladimirovna Kudryavtseva
Ural State Medical University
2 shared publications K.A. Gavrilova
Ural State Medical University
2 shared publications- R. A. Aristov
Sverdlovsk Regional Oncological Dispensary
2 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 25 (5) , 70-85
Survival Outcomes in Patients with Early and Locally Advanced BRCA1‑Associated Breast Cancer in the Sverdlovsk Region, Russia
Introduction . Breast cancer (BC) remains the leading cause of cancer morbidity among women. Hereditary forms exhibit distinct clinical behaviour and require personalized management. Despite extensive international research, the prognostic significance of BRCA-associated BC remains debated, and Russian data are scarce. The purpose of study is to analyze overall survival (OS) and progression-free survival (PFS) in patients with BRCA-associated BC in the Sverdlovsk region, and to assess these outcomes by molecular subtype. Materials and methods . This retrospective cohort study included 117 patients with stage I–III BC who underwent genetic testing by polymerase chain reaction with subsequent next-generation sequencing verification between 2018 and 2021. Group 1 comprised 53 patients with BRCA1 mutations; group 2 comprised 64 patients without BRCA1/2 mutations. Groups were matched for clinical stage and molecular subtype. Survival was estimated by Kaplan–Meier analysis with log-rank testing; independent prognostic factors were assessed using Cox proportional hazards models. Results . Five-year OS was 86.8 % in group 1 versus 76.6 % in group 2; seven-year OS was 75.5 % versus 75.0 %. Five-year PFS was 77.0 % versus 65.4 %; seven-year PFS was 74.5 % versus 65.4 %. Differences were not statistically significant. Stage-specific analysis revealed no significant differences. In multivariate Cox analysis, BRCA1 mutation status was not a significant predictor of progression or death. Triple-negative subtype, stage III, and disease progression were significant predictors of death. Conclusion . BRCA1 mutations do not worsen prognosis in BC and may be associated with more favourable survival. These findings underscore the importance of molecular genetic testing and may inform personalized treatment.
- 2 November 2026
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 25 (5) , 70-85
Open AccessSurvival Outcomes in Patients with Early and Locally Advanced BRCA1‑Associated Breast Cancer in the Sverdlovsk Region, Russia
Introduction . Breast cancer (BC) remains the leading cause of cancer morbidity among women. Hereditary forms exhibit distinct clinical behaviour and require personalized management. Despite extensive international research, the prognostic significance of BRCA-associated BC remains debated, and Russian data are scarce. The purpose of study is to analyze overall survival (OS) and progression-free survival (PFS) in patients with BRCA-associated BC in the Sverdlovsk region, and to assess these outcomes by molecular subtype. Materials and methods . This retrospective cohort study included 117 patients with stage I–III BC who underwent genetic testing by polymerase chain reaction with subsequent next-generation sequencing verification between 2018 and 2021. Group 1 comprised 53 patients with BRCA1 mutations; group 2 comprised 64 patients without BRCA1/2 mutations. Groups were matched for clinical stage and molecular subtype. Survival was estimated by Kaplan–Meier analysis with log-rank testing; independent prognostic factors were assessed using Cox proportional hazards models. Results . Five-year OS was 86.8 % in group 1 versus 76.6 % in group 2; seven-year OS was 75.5 % versus 75.0 %. Five-year PFS was 77.0 % versus 65.4 %; seven-year PFS was 74.5 % versus 65.4 %. Differences were not statistically significant. Stage-specific analysis revealed no significant differences. In multivariate Cox analysis, BRCA1 mutation status was not a significant predictor of progression or death. Triple-negative subtype, stage III, and disease progression were significant predictors of death. Conclusion . BRCA1 mutations do not worsen prognosis in BC and may be associated with more favourable survival. These findings underscore the importance of molecular genetic testing and may inform personalized treatment.
- Open Access
- 2 November 2026
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 25 (5) , 24-37
Multimodal Visual Phenotypes as a Reflection of the Biology of the Main Molecular Subtypes of Stage T1 Breast Cancer
Introduction . Breast cancer (BC) molecular subtypes differ not only in prognosis and response to systemic therapy, but also in morphological features that determine imaging appearance. A comprehensive assessment of digital mammography and ultrasound findings may reflect tumor biology and provide additional information about the probable molecular subtype at the stage of primary imaging. The purpose of the study is to identify multimodal visual phenotypes of luminal HER2‑negative, HER2‑positive, and triple-negative stage T1 BC based on the integrated assessment of digital mammography and ultrasound findings. Materials and methods . This multicenter retrospective cross-sectional study was based on archived medical records of 345 patients with morphologically verified invasive stage T1 BC. Digital mammography, breast ultrasound with color Doppler mapping and strain elastography, and morphological and immunohistochemical examinations had been performed as part of routine medical care before the data were included in the analysis. According to the immunohistochemical profile, the records were assigned to three groups: luminal HER2‑negative BC (n = 215), HER2‑ positive BC (n = 74), and triple-negative BC (n = 56). Results . Luminal HER2‑negative BC was characterized by a hyperdense mass with spiculated margins, posterior acoustic shadowing, predominantly peripheral vascularity, and high tissue stiffness. HER2‑positive BC showed a higher frequency of pleomorphic microcalcifications with linear or segmental distribution and frequent visualization of calcifications on ultrasound. Triple-negative BC was characterized by the absence of microcalcifications, posterior acoustic enhancement, mixed or intranodular vascularity, and a predominance of Tsukuba elasticity score 5. Conclusion . The main molecular subtypes of stage T1 BC demonstrate stable multimodal visual phenotypes. Integrated interpretation of mammographic and ultrasound features may serve as an additional tool for preoperative assessment of tumor biological characteristics.
- 2 November 2026
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 25 (5) , 24-37
Open AccessMultimodal Visual Phenotypes as a Reflection of the Biology of the Main Molecular Subtypes of Stage T1 Breast Cancer
Introduction . Breast cancer (BC) molecular subtypes differ not only in prognosis and response to systemic therapy, but also in morphological features that determine imaging appearance. A comprehensive assessment of digital mammography and ultrasound findings may reflect tumor biology and provide additional information about the probable molecular subtype at the stage of primary imaging. The purpose of the study is to identify multimodal visual phenotypes of luminal HER2‑negative, HER2‑positive, and triple-negative stage T1 BC based on the integrated assessment of digital mammography and ultrasound findings. Materials and methods . This multicenter retrospective cross-sectional study was based on archived medical records of 345 patients with morphologically verified invasive stage T1 BC. Digital mammography, breast ultrasound with color Doppler mapping and strain elastography, and morphological and immunohistochemical examinations had been performed as part of routine medical care before the data were included in the analysis. According to the immunohistochemical profile, the records were assigned to three groups: luminal HER2‑negative BC (n = 215), HER2‑ positive BC (n = 74), and triple-negative BC (n = 56). Results . Luminal HER2‑negative BC was characterized by a hyperdense mass with spiculated margins, posterior acoustic shadowing, predominantly peripheral vascularity, and high tissue stiffness. HER2‑positive BC showed a higher frequency of pleomorphic microcalcifications with linear or segmental distribution and frequent visualization of calcifications on ultrasound. Triple-negative BC was characterized by the absence of microcalcifications, posterior acoustic enhancement, mixed or intranodular vascularity, and a predominance of Tsukuba elasticity score 5. Conclusion . The main molecular subtypes of stage T1 BC demonstrate stable multimodal visual phenotypes. Integrated interpretation of mammographic and ultrasound features may serve as an additional tool for preoperative assessment of tumor biological characteristics.
- Open Access
- 20 October 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 22 (2) , 12-28
Lobular breast cancer in real clinical practice
Background. Lobular breast cancer (LBC) is a distinct histological subtype of breast cancer, whose incidence has significantly increased. However, breast cancer remains understudied compared to ductal breast cancer (DBC), evidenced by the lack of specific LBC-driven clinical guidelines. Aim. To establish the independence of LBC as a special form by showing its epidemiological, clinical, morphological, prognostic differences from DBC. Materials and methods. The first stage was an assessment of the incidence of DBC based on data from the Sverdlovsk region cancer registry in 2024; the second stage was an analysis of the clinical, morphological and prognostic features of DBC (n = 148) in comparison with LBC (n = 298). Results. The proportion of LBC in the overall breast cancer structure in the Sverdlovsk region in 2024 was 2.5 %. We observed a bimodal age distribution for LBC (peaks at 40–49 and 60–69 years), with a peak of 60–69 years in LBC. LBC had several features: frequent bilateral lesion, predominance of early stages and luminal subtypes, low-grade malignancy and unique microenvironment. Neoadjuvant therapy was less ineffective in LBC (pathomorphological complete response rate: 13,6 % vs. 36,4 %), primarily associated with the luminal subtypes predominance. However, aggressive LBC subtypes exhibited neoadjuvant therapy sensitivity comparable to DBC, underscoring the importance of molecular subtyping, even within distinct histology. A high frequency of positive breast cancer resection margins was associated with breast-conserving surgery, but repeat surgery to achieve negative margins significantly reduces the risk of recurrence. LBC metastases frequently involved the liver, bones, and lymph nodes; metastasis to serous membranes and ovaries was characteristic of LBC; whereas involvement of the lungs, skin and brain occurred less frequently than in DBC. Patients with LBC demonstrated superior survival compared to invasive DBC during early follow-up: 3-year disease-free survival for stage III was 78.7 % vs. 51.2 %, and 1-year overall survival for stage IV was 100 % vs. 38.9 %. Conclusion. LBC is a special form of breast cancer that has a number of features and requires more attention, research and the development of specific recommendations.
- 20 October 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 22 (2) , 12-28
Open AccessLobular breast cancer in real clinical practice
Background. Lobular breast cancer (LBC) is a distinct histological subtype of breast cancer, whose incidence has significantly increased. However, breast cancer remains understudied compared to ductal breast cancer (DBC), evidenced by the lack of specific LBC-driven clinical guidelines. Aim. To establish the independence of LBC as a special form by showing its epidemiological, clinical, morphological, prognostic differences from DBC. Materials and methods. The first stage was an assessment of the incidence of DBC based on data from the Sverdlovsk region cancer registry in 2024; the second stage was an analysis of the clinical, morphological and prognostic features of DBC (n = 148) in comparison with LBC (n = 298). Results. The proportion of LBC in the overall breast cancer structure in the Sverdlovsk region in 2024 was 2.5 %. We observed a bimodal age distribution for LBC (peaks at 40–49 and 60–69 years), with a peak of 60–69 years in LBC. LBC had several features: frequent bilateral lesion, predominance of early stages and luminal subtypes, low-grade malignancy and unique microenvironment. Neoadjuvant therapy was less ineffective in LBC (pathomorphological complete response rate: 13,6 % vs. 36,4 %), primarily associated with the luminal subtypes predominance. However, aggressive LBC subtypes exhibited neoadjuvant therapy sensitivity comparable to DBC, underscoring the importance of molecular subtyping, even within distinct histology. A high frequency of positive breast cancer resection margins was associated with breast-conserving surgery, but repeat surgery to achieve negative margins significantly reduces the risk of recurrence. LBC metastases frequently involved the liver, bones, and lymph nodes; metastasis to serous membranes and ovaries was characteristic of LBC; whereas involvement of the lungs, skin and brain occurred less frequently than in DBC. Patients with LBC demonstrated superior survival compared to invasive DBC during early follow-up: 3-year disease-free survival for stage III was 78.7 % vs. 51.2 %, and 1-year overall survival for stage IV was 100 % vs. 38.9 %. Conclusion. LBC is a special form of breast cancer that has a number of features and requires more attention, research and the development of specific recommendations.
- 11 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 114-123
Rare manifestation of atypical hemolytic uremic syndrome in pregnancy: A case report
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathy (TMA) driven by dysregulation of the alternative complement pathway. Within obstetrics, its diagnosis is critically confounded by profound clinical mimicry of common obstetrical emergencies. Delayed diagnosis is invariably associated with the rapid progression of multi-organ dysfunction syndrome (MODS), culminating in unacceptably high maternal and perinatal mortality and irreversible disability. This article presents a rare clinical case of aHUS triggered by placental abruption at 27 weeks of gestation in a patient with a history of two uncomplicated term deliveries. The initial clinical presentation was dominated by hemorrhagic shock and disseminated intravascular coagulation (DIC) secondary to massive abruption, which effectively masked the classic TMA triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. A systematic diagnostic workup including thromboelastography, schistocyte quantification, ADAMTS-13 activity assay, and renal biopsy was required to sequentially exclude other TMA subtypes and definitively establish the diagnosis. Despite a significant delay in initiating targeted therapy with the C5 complement inhibitor eculizumab and the development of severe acute kidney injury with cortical necrosis requiring prolonged renal replacement therapy (RRT), a favorable outcome was achieved. Eculizumab therapy facilitated gradual recovery of native renal function, culminating in the complete discontinuation of RRT. This case underscores placental abruption as a independent trigger for aHUS. It provides a compelling rationale for the inclusion of aHUS in the differential diagnosis of any complex obstetrical catastrophe and offers crucial clinical evidence supporting the potential for renal recovery following delayed initiation of complement blockade, even in the setting of severe, established parenchymal injury.
- 11 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 114-123
Rare manifestation of atypical hemolytic uremic syndrome in pregnancy: A case report
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathy (TMA) driven by dysregulation of the alternative complement pathway. Within obstetrics, its diagnosis is critically confounded by profound clinical mimicry of common obstetrical emergencies. Delayed diagnosis is invariably associated with the rapid progression of multi-organ dysfunction syndrome (MODS), culminating in unacceptably high maternal and perinatal mortality and irreversible disability. This article presents a rare clinical case of aHUS triggered by placental abruption at 27 weeks of gestation in a patient with a history of two uncomplicated term deliveries. The initial clinical presentation was dominated by hemorrhagic shock and disseminated intravascular coagulation (DIC) secondary to massive abruption, which effectively masked the classic TMA triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. A systematic diagnostic workup including thromboelastography, schistocyte quantification, ADAMTS-13 activity assay, and renal biopsy was required to sequentially exclude other TMA subtypes and definitively establish the diagnosis. Despite a significant delay in initiating targeted therapy with the C5 complement inhibitor eculizumab and the development of severe acute kidney injury with cortical necrosis requiring prolonged renal replacement therapy (RRT), a favorable outcome was achieved. Eculizumab therapy facilitated gradual recovery of native renal function, culminating in the complete discontinuation of RRT. This case underscores placental abruption as a independent trigger for aHUS. It provides a compelling rationale for the inclusion of aHUS in the differential diagnosis of any complex obstetrical catastrophe and offers crucial clinical evidence supporting the potential for renal recovery following delayed initiation of complement blockade, even in the setting of severe, established parenchymal injury.
- Open Access
- 28 March 2026
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 1,p. 144-148
«Mermaid syndrome»: Two clinical cases and a literature review
This study synthesizes data from current literature with a retrospective analysis of two clinical cases of sirenomelia and establishes the regional incidence of the condition within the Kurgan Region, Russia. In both cases, the lower limb fusion was accompanied by lethal visceral anomalies. The reported cases were identified via first-trimester combined prenatal screening utilizing ultrasound imaging, highlighting the critical utility of this method in the diagnosis of sirenomelia. Notably, cytogenetic analysis revealed a normal karyotype in both instances. Consequently, this study reinforces the consensus that early, expert-level sonographic assessment constitutes the definitive clinical strategy for the identification of complex, lethal fetal anomalies, thereby facilitating timely decision-making regarding pregnancy management.
- 28 March 2026
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 1,p. 144-148
Open Access«Mermaid syndrome»: Two clinical cases and a literature review
This study synthesizes data from current literature with a retrospective analysis of two clinical cases of sirenomelia and establishes the regional incidence of the condition within the Kurgan Region, Russia. In both cases, the lower limb fusion was accompanied by lethal visceral anomalies. The reported cases were identified via first-trimester combined prenatal screening utilizing ultrasound imaging, highlighting the critical utility of this method in the diagnosis of sirenomelia. Notably, cytogenetic analysis revealed a normal karyotype in both instances. Consequently, this study reinforces the consensus that early, expert-level sonographic assessment constitutes the definitive clinical strategy for the identification of complex, lethal fetal anomalies, thereby facilitating timely decision-making regarding pregnancy management.
- Open Access
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 130-140
Genetic features of breast cancer patients and women with a cancer-prone family history
Introduction . 5–10% of breast cancer (BC) cases are associated with germline pathogenic variants (PVs) in predisposition genes. In Russia, detection of “8 frequent” BRCA1,2 variants by PCR is recommended, with next generation sequensing (NGS) performed only at a second stage. Most studies on BC PVs have focused on BRCA1,2 , not exploring other candidate genes. Aim . Analyze the frequency and spectrum of PVs in candidate genes in patients with BC and healthy women with a family history of cancer. Materials and methods . Results of NGS testing (26-gene panel) on peripheral blood from 291 women were retrospectively analyzed. Participants were divided into 2 groups: 1 – patients with a history of BC (n = 146); 2 – women with 1 st /2 nd degree relatives diagnosed with BC or ovarian cancer (n = 145). Results . PVs were 2.5 times more frequent in Group 1 (21.2%) vs Group 2 (8.3%), р = 0,0012. BC onset with PVs occurred earlier than in women in whom significant genetic variants were not identified (39.3 ± 1 vs 44 ± 0,9 years, р = 0,01). PV in the BRCA1,2 genes were detected in 14.3% of group 1 and 6.2% of group 2, respectively. The most frequently detected variants were. BRCA1,2 PVs were most frequent (14.3% Grp1, 6.2% Grp2); Most common PVs were in BRCA1 : c.5266dupC, c.4035delA. BRCA1,2 PVs comprised only 68,18% of all PVs, confirming importance of testing other genes. CHEK2 PVs were frequent in Group 1 (4.8%), 7 times higher than Group 2 (р = 0,0076). CHEK2 :c.1100delC comprised 57% of these. 20.4% were VUS (variants of uncertain significance), often in non- BRCA genes. PVs in Group 2 were 8 times higher than general population rates. Conclusion . NGS enables detection of a full spectrum of clinically significant variants, requiring high expertise for interpretation.
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 130-140
Open AccessGenetic features of breast cancer patients and women with a cancer-prone family history
Introduction . 5–10% of breast cancer (BC) cases are associated with germline pathogenic variants (PVs) in predisposition genes. In Russia, detection of “8 frequent” BRCA1,2 variants by PCR is recommended, with next generation sequensing (NGS) performed only at a second stage. Most studies on BC PVs have focused on BRCA1,2 , not exploring other candidate genes. Aim . Analyze the frequency and spectrum of PVs in candidate genes in patients with BC and healthy women with a family history of cancer. Materials and methods . Results of NGS testing (26-gene panel) on peripheral blood from 291 women were retrospectively analyzed. Participants were divided into 2 groups: 1 – patients with a history of BC (n = 146); 2 – women with 1 st /2 nd degree relatives diagnosed with BC or ovarian cancer (n = 145). Results . PVs were 2.5 times more frequent in Group 1 (21.2%) vs Group 2 (8.3%), р = 0,0012. BC onset with PVs occurred earlier than in women in whom significant genetic variants were not identified (39.3 ± 1 vs 44 ± 0,9 years, р = 0,01). PV in the BRCA1,2 genes were detected in 14.3% of group 1 and 6.2% of group 2, respectively. The most frequently detected variants were. BRCA1,2 PVs were most frequent (14.3% Grp1, 6.2% Grp2); Most common PVs were in BRCA1 : c.5266dupC, c.4035delA. BRCA1,2 PVs comprised only 68,18% of all PVs, confirming importance of testing other genes. CHEK2 PVs were frequent in Group 1 (4.8%), 7 times higher than Group 2 (р = 0,0076). CHEK2 :c.1100delC comprised 57% of these. 20.4% were VUS (variants of uncertain significance), often in non- BRCA genes. PVs in Group 2 were 8 times higher than general population rates. Conclusion . NGS enables detection of a full spectrum of clinically significant variants, requiring high expertise for interpretation.
- 1 January 2025
- Published by Bulletin of the Ural Medical Academie Science in Journal of Ural Medical Academic Science
- Vol. 22 (3)
FUCOXANTHINE AS A PERSPECTIVE GEROPROTECTOR
Introduction. From 2000 to 2019, the average life expectancy increased by 6.5 years worldwide, which led to an increase in the number of diseases characteristic of old age. The search for a geroprotector capable of both increasing life expectancy and improving its quality, preventing the development of age-related diseases, is relevant. The aim of the study was to study the geroprotective properties of fucoxanthin. Materials and methods. A single-center fundamental study was conducted on 60 outbred male ICR/CD1 mice aged 20 months. 60 mice were divided into 2 groups: 1st – 30 mice that did not receive fucoxanthin, 2nd – 30 mice that received orally the drug Fucoxanthin dissolved in water (TargetMol, USA) daily for 8 months. Changes in the general biochemical parameters of blood serum were recorded using the ChemWell 2910 biochemical analyzer from Awarenesstechnology and Spinreact reagents. The total AOA of serum was determined using a Sinnowabs 3000m biochemical analyzer and Vector Best reagents. The reagent “tetramethylbenzidine (TMB) + H₂O₂” for enzyme immunoassay by Diagnostic Systems LLC is used to determine total peroxidase activity. Total AOA of liver homogenate – using the Elabscience kit E-BC-K225-M. The content of malonic dialdehyde (MDA) in liver homogenate was determined using the Elabscience kit E-BC-K025-M. The optical density during the determination of AOA and MDA in the homogenate was recorded on a Multiscan Go ThermoFisher spectrophotometer. Statistical data processing was carried out in Jamovi. The assumption of the normality of the distributions of the indicators is accepted when using the Shapiro-Wilk criterion (W>0.8). Comparison of data obeying the law of normal distribution is the Welch T–test. The survival curve is based on the Kaplan-Meyer method. The Taron-Ware criterion was chosen to calculate the reliability of changes in survival. Results. Our study confirmed the geroprotective properties of fucoxanthin against mammals, showed the antioxidant properties of the drug and the absence of pronounced toxic effects. Conclusions. Fucoxanthin can be considered as a promising geroprotector for clinical use.
- 1 January 2025
- Published by Bulletin of the Ural Medical Academie Science in Journal of Ural Medical Academic Science
- Vol. 22 (3)
FUCOXANTHINE AS A PERSPECTIVE GEROPROTECTOR
Introduction. From 2000 to 2019, the average life expectancy increased by 6.5 years worldwide, which led to an increase in the number of diseases characteristic of old age. The search for a geroprotector capable of both increasing life expectancy and improving its quality, preventing the development of age-related diseases, is relevant. The aim of the study was to study the geroprotective properties of fucoxanthin. Materials and methods. A single-center fundamental study was conducted on 60 outbred male ICR/CD1 mice aged 20 months. 60 mice were divided into 2 groups: 1st – 30 mice that did not receive fucoxanthin, 2nd – 30 mice that received orally the drug Fucoxanthin dissolved in water (TargetMol, USA) daily for 8 months. Changes in the general biochemical parameters of blood serum were recorded using the ChemWell 2910 biochemical analyzer from Awarenesstechnology and Spinreact reagents. The total AOA of serum was determined using a Sinnowabs 3000m biochemical analyzer and Vector Best reagents. The reagent “tetramethylbenzidine (TMB) + H₂O₂” for enzyme immunoassay by Diagnostic Systems LLC is used to determine total peroxidase activity. Total AOA of liver homogenate – using the Elabscience kit E-BC-K225-M. The content of malonic dialdehyde (MDA) in liver homogenate was determined using the Elabscience kit E-BC-K025-M. The optical density during the determination of AOA and MDA in the homogenate was recorded on a Multiscan Go ThermoFisher spectrophotometer. Statistical data processing was carried out in Jamovi. The assumption of the normality of the distributions of the indicators is accepted when using the Shapiro-Wilk criterion (W>0.8). Comparison of data obeying the law of normal distribution is the Welch T–test. The survival curve is based on the Kaplan-Meyer method. The Taron-Ware criterion was chosen to calculate the reliability of changes in survival. Results. Our study confirmed the geroprotective properties of fucoxanthin against mammals, showed the antioxidant properties of the drug and the absence of pronounced toxic effects. Conclusions. Fucoxanthin can be considered as a promising geroprotector for clinical use.
- 1 January 2025
- Published by Bulletin of the Ural Medical Academie Science in Journal of Ural Medical Academic Science
- Vol. 22 (1)
ANTITUMOR EFFECT OF EMF-LF (5 Hz) ON MELANOMA CELL CULTURE B16-F10
Introduction. Melanoma ranks fifth in terms of prevalence among all types of STDs in the world, demonstrating a rapid increase in the incidence rate over the past 10 years. The trend towards an increase in the prevalence of this MND, its growing resistance to existing therapies and, as a consequence, an increase in melanoma mortality indicates the need to consider new therapeutic approaches, one of which is the use of low-frequency electromagnetic fields (LF-EMF). The ability of EMF to inhibit melanoma cell population growth has been previously demonstrated, but this work is the first to investigate the effect of EMF on a melanoma cell line using an extremely low frequency — 5 Hz. The aim of the study is to identify the effect of EMF 5 Hz on the functional state of the melanoma cell line B16-F10. Materials and methods. The state of the B16-F10 melanoma cell line was analyzed after EMF irradiation (frequency 5 Hz, current force 5 A — 20 A — 30 A, single-bipolar field) for 1, 2, 3 hours. A review of the current scientific literature on the described topic. Results. In the mode of operation of the EMF 2 generator at exposition of 2 hours – increase of necrotic cells by 100% (p<0,001). In mode 3, exposure for 3 hours – increase in cells in a state of apoptosis by 24% with a pronounced dose dependence (p<0.05). Discussion. This study has confirmed that exposure to EMF-LF (5 Hz) is a promising approach in melanoma. Presumably, the observed effect (induction of oncocell death) is realized due to a change in intracellular Ca²⁺ homeostasis, which requires further research.
- 1 January 2025
- Published by Bulletin of the Ural Medical Academie Science in Journal of Ural Medical Academic Science
- Vol. 22 (1)
ANTITUMOR EFFECT OF EMF-LF (5 Hz) ON MELANOMA CELL CULTURE B16-F10
Introduction. Melanoma ranks fifth in terms of prevalence among all types of STDs in the world, demonstrating a rapid increase in the incidence rate over the past 10 years. The trend towards an increase in the prevalence of this MND, its growing resistance to existing therapies and, as a consequence, an increase in melanoma mortality indicates the need to consider new therapeutic approaches, one of which is the use of low-frequency electromagnetic fields (LF-EMF). The ability of EMF to inhibit melanoma cell population growth has been previously demonstrated, but this work is the first to investigate the effect of EMF on a melanoma cell line using an extremely low frequency — 5 Hz. The aim of the study is to identify the effect of EMF 5 Hz on the functional state of the melanoma cell line B16-F10. Materials and methods. The state of the B16-F10 melanoma cell line was analyzed after EMF irradiation (frequency 5 Hz, current force 5 A — 20 A — 30 A, single-bipolar field) for 1, 2, 3 hours. A review of the current scientific literature on the described topic. Results. In the mode of operation of the EMF 2 generator at exposition of 2 hours – increase of necrotic cells by 100% (p<0,001). In mode 3, exposure for 3 hours – increase in cells in a state of apoptosis by 24% with a pronounced dose dependence (p<0.05). Discussion. This study has confirmed that exposure to EMF-LF (5 Hz) is a promising approach in melanoma. Presumably, the observed effect (induction of oncocell death) is realized due to a change in intracellular Ca²⁺ homeostasis, which requires further research.